Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03484299 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 29, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study completion date: Jul 31, 2026 to Jul 31, 2027
    • Site contact updated
    v10
  2. Site contact updatedv9
  3. Primary completion date: Dec 31, 2023 to Jul 31, 2026
    • Study completion date: Jul 31, 2024 to Jul 31, 2026
    • Site contact updated
    v8
  4. Re-verified, no change to tracked fieldsv7
  5. Primary completion date: Dec 31, 2022 to Dec 31, 2023
    • Study completion date: Dec 31, 2023 to Jul 31, 2024
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. 3 versions Re-verified since Jul 30, 2021, no change to tracked fieldsv3-v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2, 2018 to May 30, 2018
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
Trial Details
NCT Number NCT03484299
Lead Sponsor University of Louisville
Conditions
(from sponsor)		 Pancreas Cancer
Related terms Pancreatic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov